A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- NA · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 21
- Population
- ALL · 50 Years to 85 Years
- Duration
- 2021-02-04 to 2028-01-01
- Intervention
- Atorvastatin 80mg
- Comparator
- Not reported
- Outcomes measured
- Change in Dark Adaptation recovery time measured by change in Rod Intercept time (RIT) — 18 Months; Change in drusen volume measured by Spectral Domain OCT — 18 months; To correlate visual functions of dark adaption with change in drusen volume — 18 months; To correlate Best Corrected Visual Acuity and retinal structural evaluation of study patients — 18 months; To correlate change in contrast sensitivity and retinal structural evaluation of study patients — 18 months; To correlate change in microperimetry visual functional and retinal structural evaluation of study patients — 18 months
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.
